PSA screening-for whom and when?  

作　　者：Peter Albers 

机构地区：[1]Department of Urology,Dusseldorf University Hospital,Heinrich-Heine-University,Moorenstr.5, D-40225,Dusseldorf,Germany.

出　　处：《Asian Journal of Andrology》2019年第1期3-5,共3页亚洲男性学杂志（英文版）

摘　　要：Reasons for and against screening of,prostate cancer have been discussed widely over the last decade.In 2014,the European Randomized Trial for Screening of Prostate Cancer(ERSPC)has reported a relative reduction of the cancer-specific survival of 27%in participants who definitely followed the screeningprotocol.This relative advantage has proven to be stable from year 7 to year 13 after the beginning of screening.Still,the disadvantages of overdiagnosis and overtreatment are the downsides of a population-based screening approach.But given the overall advantage of screening,a risk-adapted prostate-specific antigen(PSA)screening using a baseline PSA value at ages 45-50 may significantly reduce the number needed to diagnose maintaining the benefits of screening.PROBASE is a randomized risk-adapted screening trial currently ongoing in Germany to answer this important question.

关 键 词：PSA ERSPC 

分 类 号：R[医药卫生]